Mariya Rozenblit
Overview
Explore the profile of Mariya Rozenblit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
539
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lambertini M, Blondeaux E, Tomasello L, Agostinetto E, Hamy A, Kim H, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401334.
PMID: 39993249
Purpose: To investigate the clinical behavior of breast cancer in young carriers according to the specific gene () and the association of the timing of genetic testing (before at diagnosis)...
2.
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, et al.
Breast Cancer Res Treat
. 2024 Nov;
209(1):21-26.
PMID: 39602012
Introduction: It is incompletely understood why some women develop breast cancer 15-20 years earlier than the majority of women. We hypothesize that women with early-onset breast cancer and high-risk family...
3.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
4.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
5.
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim H, Di Meglio A, et al.
Cancer
. 2024 May;
130(16):2746-2762.
PMID: 38752572
Background: Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor...
6.
Lambertini M, Blondeaux E, Agostinetto E, Hamy A, Kim H, Di Meglio A, et al.
JAMA
. 2023 Dec;
331(1):49-59.
PMID: 38059899
Importance: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in...
7.
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, et al.
Breast Cancer Res Treat
. 2023 Nov;
204(1):181-185.
PMID: 37999916
Purpose: Approximately 5% of breast cancers each year are diagnosed in young women < 40 years who tend to have worse clinical outcomes. We compared genomic alterations using comprehensive genomic...
8.
Lin H, Can T, Kahn A, Flannery C, Hoag J, Akkunuri A, et al.
Oncologist
. 2023 Sep;
28(10):e973-e976.
PMID: 37656608
Background: HER2 immunohistochemistry (IHC) reproducibility is suboptimal for HER-low cases (IHC 1+ or 2+). Methods: The Yale cohort included 214 stages I-II estrogen receptor positive breast cancers with IHC scores...
9.
Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, et al.
J Clin Oncol
. 2023 Aug;
41(34):5237-5241.
PMID: 37607325
No abstract available.
10.
Minteer C, Thrush K, Gonzalez J, Niimi P, Rozenblit M, Rozowsky J, et al.
Sci Adv
. 2023 Jul;
9(29):eadf4163.
PMID: 37467337
Aging is a leading risk factor for cancer. While it is proposed that age-related accumulation of somatic mutations drives this relationship, it is likely not the full story. We show...